Landmarks in Hormonal Therapy for Prostate Cancer
Loading...
Start Date
6-1-2012 9:00 AM
End Date
6-1-2012 10:00 AM
Description
Presentation: 1 hour and 7 minutes.
Learning Objectives:
1. At the conclusion of presentation, to be able to discuss the complexities of the hypothalamic-pituitary-testicular axis
2. To describe the testosterone thresholds associated with various LHRH compounds and outcomes.
3. To describe the effects of various hormonal agents on FSH, LH and PSA.
Landmarks in Hormonal Therapy for Prostate Cancer
Presentation: 1 hour and 7 minutes.
Learning Objectives:
1. At the conclusion of presentation, to be able to discuss the complexities of the hypothalamic-pituitary-testicular axis
2. To describe the testosterone thresholds associated with various LHRH compounds and outcomes.
3. To describe the effects of various hormonal agents on FSH, LH and PSA.
Comments
E. David Crawford, M.D., is a professor of surgery, urology, and radiation oncology and head of urologic oncology in the Urologic Oncology Department at the University of Colorado Denver in Aurora, Colorado. He also serves as associate director of the University of Colorado Cancer Center in Denver.
Dr. Crawford earned his medical degree from the University of Cincinnati in Ohio. He completed his residency in the Department of Surgery at Good Samaritan Hospital in Cincinnati, followed by a clinical fellowship in urology at the University of California Medical Center in Los Angeles. He is a fellow of the American College of Surgeons and board certified by the American Board of Urology.
Considered a "legend in urology" by the Canadian Journal of Urology, Dr. Crawford has been the recipient of numerous research grants and has participated in several Southwest Oncology Group and National Cancer Institute protocols. In addition, to his tenure of chair of the genitourinary committee for the Southwest Oncology Group for 28 years and current chair of the National Prostate Cancer Education Council, Dr. Crawford is a member of the Prostate Cancer Trialists Collaborative Group and the Alliance for Prostate Cancer Prevention.